AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22538327
Drug: Prostacyclin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin treatment
Trial: 16130055
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1 g every sixth hour)
Trial: 16130055
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (1 g every sixth hour)
Trial: 12404086
Drug: Acute tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute tryptophan depletion (ATD) via oral mixture of amino acids
Trial: 31606734
Drug: Integrase strand
RxNorm normalized name: Integrase strand transfer inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase strand transfer inhibitors (ISTIs)
Trial: 30712404
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of IM olanzapine
Trial: 30712404
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of oral clonidine
Trial: 25600568
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with second-line chemotherapy (mFOLFOX-6 or FOLFIRI)
Trial: 25600568
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (mFOLFOX-6 or FOLFIRI without bevacizumab)
Trial: 23831423
Drug: TENS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS treatment for 3 weeks (1 hour per day) on the median nerve region of the most impaired hand
Trial: 21966856
Drug: Letrozole, 2.5
RxNorm normalized name: Letrozole, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole, 2.5 mg, oral route for 36 months
Trial: 21966856
Drug: Tamoxifen, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen, 20 mg, oral route for 36 months
Trial: 19948980
Drug: Hyperglycemia (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (glucose > or =140 mg/dL) on admission
Trial: 19948980
Drug: Hyperglycemia (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (glucose > or =140 mg/dL) after admission
Trial: 19948980
Drug: Hypoglycemia (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (glucose < or =70 mg/dL) on admission
Trial: 19948980
Drug: Hypoglycemia (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (glucose < or =70 mg/dL) postadmission
Trial: 19948980
Drug: Hypoglycemia redefined
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia redefined as glucose < or =60 mg/dL
Trial: 19948980
Drug: Postadmission hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postadmission hypoglycemia in insulin-treated patients
Trial: 11103165
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin delivered by J-Tip
Trial: 11103165
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin delivered by standard needle and syringe
Trial: 3746543
Drug: IVIgG (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIgG (both low and high doses)
Trial: 2453995
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream (EMLA) applied topically, 10 g one hour before operation
Trial: 31770084
Drug: Bio-sorb® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-sorb® cream
Trial: 31770084
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cream)
Trial: 21255869
Drug: Nonablative 1550-nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative 1550-nm fractional laser therapy
Trial: 21255869
Drug: Triple topical
RxNorm normalized name: Triple Paste Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple topical therapy (hydroquinone 5%, tretinoin 0.05%, and triamcinolone acetonide 0.1% cream)
Trial: 10848682
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (INO) at 4 parts per million
Trial: 10848682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INO and PEEP at 10 cm H2O
Trial: 26586327
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist exenatide (acute intervention)
Trial: 26586327
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist liraglutide (12-week intervention)
Trial: 26586327
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor sitagliptin (12-week intervention)
Trial: 23896631
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation (45.0 Gy and boost up to 54.0 Gy plus concurrent and subsequent gemcitabine)
Trial: 20043816
Drug: SB-742457 35
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-742457 35 mg
Trial: 20043816
Drug: SB-742457 5
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-742457 5 mg
Trial: 20043816
Drug: SB-742457 15
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-742457 15 mg
Trial: 17804302
Drug: School-based supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based supervised asthma therapy
Trial: 17804302
Drug: Parent supervised
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent supervised asthma therapy
Trial: 10192233
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg/day)
Trial: 10192233
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 40 mg/day)
Trial: 1970027
Drug: Doxapram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram infusion (2 mg per min for 6 h immediately after surgery and repeated on the first postoperative day)
Trial: 1970027
Drug: Doxapram infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram infusion
Trial: 24905260
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading (Columbus Bridge Protocol) with 4 to 6 implants, loaded within 24 hours
Trial: 24905260
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading (two-stage surgical protocol) with 6 to 9 straight implants, loaded a mean of 8.75 months after surgery
Trial: 19371389
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment applied (Group G2)
Trial: 17911499
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg/d for 24 weeks)
Trial: 9727729
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg chlorazepate
Trial: 9727729
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oxazepam
Trial: 2532841
Drug: etretin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etretin (50 mg/day)
Trial: 19445822
Drug: Caffeine alone
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine alone (150 mg)
Trial: 19445822
Drug: Caffeine plus
RxNorm normalized name: Caffeine Plus Green Tea Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine plus a catechin mixture (600 mg) enriched in EGCG
Trial: 16786231
Drug: On-site fibrin-specific
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site fibrin-specific thrombolytic therapy (TT)
Trial: 14962331
Drug: Roc 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roc 0.4 mg.kg(‐1)
Trial: 14962331
Drug: Miv 0.133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miv 0.133 mg.kg(‐1)
Trial: 14962331
Drug: Roc 0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roc 0.32 + Miv 0.027 mg.kg(‐1)
Trial: 14962331
Drug: Roc 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roc 0.24 + Miv 0.053 mg.kg(‐1)
Trial: 14962331
Drug: Roc 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roc 0.16 + Miv 0.08 mg.kg(‐1)
Trial: 14962331
Drug: Roc 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roc 0.08 + Miv 0.106 mg.kg(‐1)
Trial: 14962331
Drug: Combination groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination groups (Roc + Miv)
Trial: 11098963
Drug: Filgrastim 300
RxNorm normalized name: FILGRASTIM 300MCG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 300 microg subcutaneously once daily for 7 days
Trial: 9049456
Drug: Electrolyte-poor water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte-poor water supplementation (2 L/day)
Trial: 9049456
Drug: HCO3-rich water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCO3-rich water supplementation (2 L/day, 47.5 mmol/L)
Trial: 8075257
Drug: Ampicillin/sulbactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (3 g every 6 hours)
Trial: 8075257
Drug: Imipenem/cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (500 mg every 6 hours)
Trial: 20693570
Drug: Self-reported answer
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported answer to a question about drinking quantity (weekly consumption of 8 or more standard drinks) within the past 90 days
Trial: 16098074
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment arm (idarubicin 42 mg/m2, melphalan 200 mg/m2, cyclophosphamide 120 mg/kg)
Trial: 16098074
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm (melphalan 200 mg/m2)
Trial: 10616771
Drug: OAC1w (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC1w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 1 week)
Trial: 10616771
Drug: OAC2w (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC2w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 2 weeks)
Trial: 8572853
Drug: One-hour course
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-hour course about diet (CC)
Trial: 2695413
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (550 mg twice daily, from day -7 to the 4th day of the cycle)
Trial: 321147
Drug: Acetyl strophanthanin
RxNorm normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl strophanthanin (0.5 mg initially, followed by 0.25 mg four hours later)
Trial: 25664155
Drug: Nefopam 40
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 40 mg mixed with normal saline 100 ml (Group N)
Trial: 23307959
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg PEA, twice a day for three months (T1)
Trial: 23307959
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg PEA, after washout period (T3)
Trial: 16432054
Drug: L-arginine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine + ramipril
Trial: 16432054
Drug: L-NG-nitro-arginine-methyl-ester (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NG-nitro-arginine-methyl-ester (2 mg/kg) during ramipril
Trial: 14768658
Drug: Cafeteria-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafeteria-based intervention including daily activities to increase availability, attractiveness, and encouragement for fruit and vegetable consumption, along with special events over two school years.
Trial: 11765593
Drug: Prednisolone 50
RxNorm normalized name: prednisolone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 50 mg Ferring tablets (test preparation)
Trial: 11765593
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (control)
Trial: 8393019
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (3 x 4 mg)
Trial: 25842202
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (demographically similar, N = 32, scanned twice)
Trial: 24515256
Drug: Lifestyle counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle counseling (LC) plus metformin (target dose of 1,000 mg twice daily)
Trial: 22505373
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 300 mg q.i.d., esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., and amoxicillin 1 g b.i.d. (bismuth group)
Trial: 22505373
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg b.i.d., tetracycline 500 mg q.i.d., amoxicillin 1 g b.i.d., and metronidazole 500 mg t.i.d. (concomitant group)
Trial: 20386337
Drug: Diabetes medication
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes medication usage and history of cardiovascular disease
Trial: 12859471
Drug: 15 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml.kg‐1 Hartmann's solution (supplemental fluid)
Trial: 12859471
Drug: 2 ml.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml.kg‐1 Hartmann's solution (conservative fluid)
Trial: 10690832
Drug: Intravenous broad-spectrum
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous broad-spectrum antibiotic immediately after induction of anesthesia (group 1)
Trial: 10690832
Drug: Postoperative course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative course of oral antibiotics (group 3)
Trial: 8645644
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.7 g/day n‐3 fatty acids)
Trial: 29953304
Drug: Internet-Based Mindfulness-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Based Mindfulness-Based Cognitive Therapy (eMBCT)
Trial: 27621609
Drug: Albuterol (4×100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (4×100 μg/puff in the UK; 4×90 μg/puff in the US)
Trial: 27621609
Drug: Ipratropium (4×20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (4×20 μg/puff)
Trial: 23663079
Drug: Sedative music
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative music played for the first hour in bed
Trial: 18925392
Drug: Recombinant IL-21
RxNorm normalized name: Human il-12 (recombinant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant IL-21 (rIL-21) administered by intravenous bolus injection at dose levels from 1 to 100 microg/kg
Trial: 18925392
Drug: 5 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 + 9 dosing regimen of rIL-21
Trial: 18925392
Drug: 3/w dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3/w dosing regimen of rIL-21
Trial: 15378666
Drug: milnacipran (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milnacipran (up to 200 mg/day)
Trial: 15378666
Drug: milnacipran (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milnacipran (twice daily)
Trial: 11556124
Drug: 10 x
RxNorm normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 x 2 mg prednisolone tablets
Trial: 11556124
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 5 mg prednisolone tablets
Trial: 11556124
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prednisolone tablet formulation
Trial: 3416729
Drug: Alcohol doses
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol doses (0.25, 0.5 and 0.75 g/kg of 95% ethanol)
Trial: 29900909
Drug: Chronic generalized
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic generalized periodontitis (Group II) before treatment
Trial: 27404009
Drug: Smartphone raffle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone raffle intervention (weekly for clients, monthly for peer promoters and providers)
Trial: 24096084
Drug: Purported weight-loss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purported weight-loss supplement (placebo)
Trial: 21443756
Drug: Cream A
RxNorm normalized name: KIT, CREAM AND GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream A [3% PLA-retinyl retinoate (2%) microsphere] applied twice daily
Trial: 21443756
Drug: Cream B
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream B (0.06% retinyl retinoate) applied twice daily
Trial: 18753058
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive treatment with directional soft tube placement
Trial: 18753058
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (medication)
Trial: 12091260
Drug: Citalopram 20-40
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20-40 mg for 8 weeks followed by 16 weeks of fixed dose and then randomisation to citalopram for at least 48 weeks
Trial: 11185677
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg/day)
Trial: 8543937
Drug: Theophylline 150
RxNorm normalized name: theophylline 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 150 mg/day
Trial: 2037418
Drug: Phenol treatment
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenol treatment on tympanic membrane prior to myringotomy
Trial: 2037418
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no phenol treatment)
Trial: 7016224
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy alone
Trial: 7016224
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy plus living BCG vaccinations
Trial: 28115667
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of zinc
Trial: 28115667
Drug: Both 2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 2,500 IU of vitamin A and 25 mg of zinc
Trial: 25887759
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continuing with the treatment allocated in the ADDITION study
Trial: 15972619
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 50 mg injections every 3 weeks
Trial: 12812849
Drug: Fractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated stereotactic radiotherapy (SRT) boost to 20 Gy in four fractions following partial brain irradiation to a dose of 60 Gy in 30 fractions
Trial: 10319907
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg/day plus cyproheptadine 24 mg/day
Trial: 10319907
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg/day plus placebo
Trial: 8532270
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg, three times per day from 36 weeks' gestation until delivery
Trial: 3314973
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg
Trial: 3066417
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam
Trial: 21143248
Drug: L-cysteine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-cysteine (200 mg)
Trial: 19321405
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin
Trial: 17156222
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg administered intravenously 30 min before the end of surgery